Jonas de Souza, MD, assistant professor of Medicine, University of Chicago Medicine, discusses some of the upcoming next steps regarding immunotherapy in head and neck cancer.
Jonas de Souza, MD
Advertisement
Articles by Jonas de Souza, MD
Jonas de Souza, MD, assistant professor of medicine, University of Chicago, discusses the approval of pembrolizumab for relapsed head and neck cancer patients who are platinum-refractory
Advertisement
Latest Updated Articles
Dr. Jonas de Souza on the Impact of Pembrolizumab Approval in Head and Neck CancerPublished: October 5th 2016 | Updated:
Dr. de Souza on Next Steps for Immunotherapy in Head and Neck CancerPublished: December 20th 2016 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
2
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
3
FDA Grants Fast Track Designation to IBI3003 in Relapsed/Refractory Multiple Myeloma
4
Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies
5